Special Issue

Metabolomics and/or Biomarkers for Drug Discovery

Message from the Guest Editor

Metabolomics is the study of biological systems using an integrated approach. It focuses mainly on profiling small-molecule metabolites (metabolic profiling), and differs from genomics and proteomics which characterize the profiles of genes and proteins. respectively. On the other hand, biomarkers are objectively and quantitatively measurable indicators of biological or pathogenic processes. Both metabolomics and biomarkers are increasingly used in drug discovery and development, managing disease progression and personalized medicine. This Special Issue is devoted to the application of metabolomics and/or biomarkers in drug discovery and development. Topics covered by this Special Issue will include (not exclusively): Identification of metabolites and/or biomarkers as targets for drugs and natural health products, validation of targets derived from metabolomics and/or biomarkers, metabolites and/or biomarkers as therapeutics, metabolomics and/or biomarkers for drug development, disease modeling and management, and personalized medicine.


Guest Editor

Prof. Dr. Pollen K. Yeung

Professor of Pharmacy and Medicine, College of Pharmacy, Dalhousie University, Halifax, NS B3H 4R2, Canada

Deadline for manuscript submissions

closed (28 February 2018)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/7776

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

